

---

# 5.50.012

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2023
<b>Subsection:</b>	Gastrointestinal Agents	<b>Original Policy Date:</b>	October 1, 2014
<b>Subject:</b>	Entyvio (IV)	<b>Page:</b>	1 of 7

---

**Last Review Date:** December 2, 2022

---

## Entyvio (IV)

### Description

Entyvio (vedolizumab) for injection, for intravenous use

### Background

Entyvio (vedolizumab) is a humanized monoclonal antibody that specifically binds to the  $\alpha 4\beta 7$  integrin and blocks the interaction of  $\alpha 4\beta 7$  integrin with mucosal addressing cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. The  $\alpha 4\beta 7$  integrin is expressed on the surface of a discrete subset of memory T-lymphocytes that preferentially migrate into the gastrointestinal tract. MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T-lymphocytes to gut lymph tissue. The interaction of the  $\alpha 4\beta 7$  integrin with MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn's disease (1).

### Regulatory Status

FDA-approved indications: Entyvio is an integrin receptor antagonist indicated for adults in the treatment of: (1)

1. Moderately to severely active ulcerative colitis (UC)
2. Moderately to severely active Crohn's disease (CD)

Entyvio has warnings for infusion-related reactions and hypersensitivity reactions, infections, and progressive multifocal leukoencephalopathy (PML). Entyvio is not recommended in patients with active, severe infections until the infections are controlled. Patients who develop a severe infection while on treatment with Entyvio should have treatment withheld. Although unlikely, a

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2023
<b>Subsection:</b>	Gastrointestinal Agents	<b>Original Policy Date:</b>	October 1, 2014
<b>Subject:</b>	Entyvio (IV)	<b>Page:</b>	2 of 7

---

risk of PML cannot be ruled out. Patients should be monitored for any new or worsening neurological signs or symptoms (1).

Physicians will need to discontinue therapy in patients who show no evidence of therapeutic benefit by week 14 (1).

The safety and effectiveness of Entyvio in pediatric patients have not been established (1).

## Related policies

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Entyvio may be considered **medically necessary** in patients 18 years of age or older for the treatment of ulcerative colitis and Crohn's disease; and if the conditions indicated below are met.

Entyvio may be considered **investigational** in patients less than 18 years of age and for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. Moderate to severely active Ulcerative Colitis (UC)
2. Moderate to severely active Crohn's Disease (CD)

**AND ALL** of the following:

- a. Inadequate treatment response, intolerance, or contraindication to at least **ONE** conventional therapy option (see Appendix 1)
- b. Inadequate response, intolerance, or contraindication to a biologic DMARD or targeted synthetic DMARD (see Appendix 2) if adjudicated through the pharmacy benefit

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2023
<b>Subsection:</b>	Gastrointestinal Agents	<b>Original Policy Date:</b>	October 1, 2014
<b>Subject:</b>	Entyvio (IV)	<b>Page:</b>	3 of 7

---

- c. Patient's condition will be re-evaluated at week 14 to confirm if therapy with Entyvio may continue
- d. Prescriber will be dosing the patient within the FDA labeled maintenance dose of 300 mg every 8 weeks
- e. **NOT** to be used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 2)

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

- 1. Ulcerative Colitis (UC)
- 2. Crohn's Disease (CD)

**AND ALL** of the following:

- a. Prescriber will be dosing the patient within the FDA labeled maintenance dose of 300 mg every 8 weeks
- b. **NOT** to be used in combination with any other biologic DMARD or targeted synthetic DMARD (see Appendix 2)

## Policy Guidelines

### Pre - PA Allowance

None

### Prior - Approval Limits

**Quantity** 9 vials  
(1 vial each at weeks 0, 2, and 6 and then maintenance dosing of 1 vial every 8 weeks)

**Duration** 12 months

### Prior – Approval *Renewal* Limits

**Quantity** 10 vials

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2023
<b>Subsection:</b>	Gastrointestinal Agents	<b>Original Policy Date:</b>	October 1, 2014
<b>Subject:</b>	Entyvio (IV)	<b>Page:</b>	4 of 7

**Duration** 18 months

## Rationale

### Summary

Entyvio (vedolizumab) is an integrin receptor antagonist indicated for adults in the treatment of moderate to severely active ulcerative colitis and moderate to severely active Crohn's disease. Entyvio has warnings for infusion-related reactions and hypersensitivity reactions, infections, and progressive multifocal leukoencephalopathy (PML). Therapy should be discontinued in patients who show no evidence of therapeutic benefit after the first 14 weeks of treatment. The safety and effectiveness of Entyvio in pediatric patients have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Entyvio while maintaining optimal therapeutic outcomes.

### References

1. Entyvio [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; June 2022.

## Policy History

Date	Action
June 2014	New Policy Addition
September 2014	Addition of no concurrent use with Kineret from SME
March 2015	Annual editorial review and reference update
September 2015	Annual review
December 2016	Annual editorial review Addition of age to renewal requirements, removal of examples of TNF blocker and interleukin antagonists from criteria Policy number change from 5.18.09 to 5.50.12
March 2017	Annual editorial review and reference update Addition of no concurrent use with TNF blockers, Kineret and Tysabri to renewal criteria and prior PA initiation duration changed from 3 months to 4 months
March 2018	Annual editorial review Addition of Appendix 1 - List of Conventional Therapies
June 2018	Addition of dosage limit requirements Addition of Appendix 2 - List of DMARDs

# 5.50.012

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2023
<b>Subsection:</b>	Gastrointestinal Agents	<b>Original Policy Date:</b>	October 1, 2014
<b>Subject:</b>	Entyvio (IV)	<b>Page:</b>	5 of 7

---

	Removal of inadequate response with, or lost response to or was not able to tolerate an immunomodulator and inadequate response with, or lost response to or demonstrated dependence on corticosteroids and changed to inadequate response, intolerance or contraindication to at least ONE conventional therapy option (see Appendix 1)
September 2018	Annual editorial review
March 2019	Annual review
December 2019	Annual review and reference update. Addition of requirement to trial preferred product
March 2020	Annual review
August 2020	Clarifying language added to pharmacy benefit
December 2020	Annual review and reference update. Removed requirement to t/f preferred product Humira. Moved requirement to reevaluate condition at week 14 from continuation to initiation. Changed approval durations to 12 months and 18 months. Added PA quantity limits. Added initiation requirement to t/f a biologic or targeted synthetic DMARD per FEP. Changed policy name from Entyvio to Entyvio (IV) per FEP.
March 2021	Annual editorial review. Clarification added to the t/f, intolerance, C/I to a biologic or targeted synthetic DMARD requirement indicating that it only applies to claims adjudicated through the pharmacy benefit. Updated Appendix 2.
June 2021	Annual editorial review
March 2022	Annual review and reference update
September 2022	Annual review and reference update
December 2022	Annual review

## Keywords

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 2, 2022 and is effective on January 1, 2023.**

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2023
<b>Subsection:</b>	Gastrointestinal Agents	<b>Original Policy Date:</b>	October 1, 2014
<b>Subject:</b>	Entyvio (IV)	<b>Page:</b>	6 of 7

### APPENDIX 1 – List of Conventional Therapies

<b>Conventional Therapy Options for CD</b>	
1. Mild to moderate disease – induction of remission:	<ul style="list-style-type: none"> <li>a. Oral budesonide, oral mesalamine</li> <li>b. Alternatives: metronidazole, ciprofloxacin</li> </ul>
2. Mild to moderate disease – maintenance of remission:	<ul style="list-style-type: none"> <li>a. Azathioprine, mercaptopurine</li> <li>b. Alternatives: oral budesonide, methotrexate intramuscularly (IM)</li> </ul>
3. Moderate to severe disease – induction of remission:	<ul style="list-style-type: none"> <li>a. Prednisone, methylprednisolone intravenously (IV)</li> <li>b. Alternatives: methotrexate IM</li> </ul>
4. Moderate to severe disease – maintenance of remission:	<ul style="list-style-type: none"> <li>a. Azathioprine, mercaptopurine</li> <li>b. Alternative: methotrexate IM</li> </ul>
5. Perianal and fistulizing disease – induction of remission	<ul style="list-style-type: none"> <li>c. Metronidazole ± ciprofloxacin</li> </ul>
6. Perianal and fistulizing disease – maintenance of remission	<ul style="list-style-type: none"> <li>d. Azathioprine, mercaptopurine</li> <li>e. Alternative: methotrexate IM</li> </ul>

  

<b>Conventional Therapy Options for UC</b>	
1. Mild to moderate disease – induction of remission:	<ul style="list-style-type: none"> <li>a. Oral mesalamine (e.g., Asacol, Lialda, Pentasa), balsalazide, olsalazine</li> <li>b. Rectal mesalamine (e.g., Canasa, Rowasa)</li> <li>c. Rectal hydrocortisone (e.g., Colocort, Cortifoam)</li> <li>d. Alternatives: prednisone, azathioprine, mercaptopurine, sulfasalazine</li> </ul>
2. Mild to moderate disease – maintenance of remission:	<ul style="list-style-type: none"> <li>a. Oral mesalamine, balsalazide, olsalazine, rectal mesalamine</li> <li>b. Alternatives: azathioprine, mercaptopurine, sulfasalazine</li> </ul>
3. Severe disease – induction of remission:	<ul style="list-style-type: none"> <li>a. Prednisone, hydrocortisone IV, methylprednisolone IV</li> <li>b. Alternatives: cyclosporine IV, tacrolimus, sulfasalazine</li> </ul>
4. Severe disease – maintenance of remission:	<ul style="list-style-type: none"> <li>a. Azathioprine, mercaptopurine</li> <li>b. Alternative: sulfasalazine</li> </ul>
5. Pouchitis:	<ul style="list-style-type: none"> <li>a. Metronidazole, ciprofloxacin</li> <li>b. Alternative: rectal mesalamine</li> </ul>

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2023
<b>Subsection:</b>	Gastrointestinal Agents	<b>Original Policy Date:</b>	October 1, 2014
<b>Subject:</b>	Entyvio (IV)	<b>Page:</b>	7 of 7

## Appendix 2 – List of DMARDs

### Biological disease-modifying drugs (DMARDs)

Generic Name	Brand Name
abatacept	Orencia
adalimumab	Humira
anakinra	Kineret
brodalumab	Siliq
certolizumab	Cimzia
etanercept	Enbrel
golimumab	Simponi/Simponi Aria
guselkumab	Tremfya
infliximab	Remicade/Avsola/Inflectra/Renflexis
ixekizumab	Taltz
risankizumab-rzaa	Skyrizi
rituximab	Rituxan/Riabni/Ruxience/Truxima
sarilumab	Kevzara
secukinumab	Cosentyx
spesolimab-sbzo	Spevigo
tildrakizumab-asmn	Ilumya
tocilizumab	Actemra
ustekinumab	Stelara
vedolizumab	Entyvio

### Targeted synthetic disease-modifying drugs (DMARDs)

Generic Name	Brand Name
apremilast	Otezla
baricitinib	Olumiant
deucravacitinib	Sotyktu
tofacitinib	Xeljanz/XR
upadactinib	Rinvoq